Mutant butterflies reveal the genetic roots of colorful wings – Washington Post
Nature.com |
Mutant butterflies reveal the genetic roots of colorful wings
Washington Post The authors of the new study rearranged colors on butterfly wings by deleting a single gene using a genome editing tool called CRISPR. The gene’s absence had a dramatic effect in seven butterfly species, including some that aren’t closely related. CRISPR reveals genetic master switches behind butterfly wing patternsNature.com Butterfly wing patterns altered with CRISPR offer insights into evolution of biodiversityNew Atlas Genetic master switch for butterfly wing coloring found with CRISPRZME Science New Scientist –New York Times –Capitalberg all 15 news articles » |
Nature.com |
Mutant butterflies reveal the genetic roots of colorful wings
Washington Post The authors of the new study rearranged colors on butterfly wings by deleting a single gene using a genome editing tool called CRISPR. The gene’s absence had a dramatic effect in seven butterfly species, including some that aren’t closely related. CRISPR reveals genetic master switches behind butterfly wing patternsNature.com Butterfly wing patterns altered with CRISPR offer insights into evolution of biodiversityNew Atlas Genetic master switch for butterfly wing coloring found with CRISPRZME Science New Scientist –New York Times –Capitalberg all 15 news articles » |
Investopedia |
Yes, Juno Therapeutics (JUNO) Just Became a Great CAR–T Trade
Investorplace.com CAR-T, short for chimeric antigen receptor T–cells, are simply a way of describing the modification of a patient’s disease-fighting T calls to recognize and attack cancerous cells they may not have been able to “see” and kill before. It’s an effective … Kite Pharma, Inc. (NASDAQ:KITE) Sees Heavy Trading Volume with 2109K Shares Changing HandsHighlight Press |
EPM Magazine |
Three CAR–T cell therapy studies announced from UK start-up Autolus
EPM Magazine AUTO2 and AUTO3 are both dual targeting CAR–T cell therapies. The announcement of the trials evaluating these two therapies comes on the back of the recent FDA approval of Novartis’ CAR–T cell therapy, and Gilead’s proposed acquisition of Kite Pharma … |
EPM Magazine |
Three CAR–T cell therapy studies announced from UK start-up Autolus
EPM Magazine AUTO2 and AUTO3 are both dual targeting CAR–T cell therapies. The announcement of the trials evaluating these two therapies comes on the back of the recent FDA approval of Novartis’ CAR–T cell therapy, and Gilead’s proposed acquisition of Kite Pharma … |
Xconomy |
On CAR–T’s Edge, Seattle Researchers Plot to Bypass Novartis Therapy
Xconomy It’s not a stretch to say that Greta Oberhofer is alive thanks to the genetically modified cell therapy called CAR–T. At three and a half months old, she was diagnosed with acute lymphoblastic leukemia, or ALL, an aggressive blood cancer. At 10 months … |
STAT |
Not just for CRISPR: Lemelson-MIT Prize honors Feng Zhang for ‘big ideas that change fields’
STAT Although Zhang 2, whose lab is at the Broad Institute of MIT and Harvard, is best known for CRISPR advances such as editing genes 3 in human and mouse cells, he wasn’t honored only for that, said bioengineer Michael Cima of MIT’s Koch Institute, the … Gene-editing technology developer Feng Zhang awarded $500000 Lemelson-MIT PrizeMIT News |
STAT |
Not just for CRISPR: Lemelson-MIT Prize honors Feng Zhang for ‘big ideas that change fields’
STAT Although Zhang 2, whose lab is at the Broad Institute of MIT and Harvard, is best known for CRISPR advances such as editing genes 3 in human and mouse cells, he wasn’t honored only for that, said bioengineer Michael Cima of MIT’s Koch Institute, the … Gene-editing technology developer Feng Zhang awarded $500000 Lemelson-MIT PrizeMIT News |